

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

Cell-Specific Adenovirus





FIG. 1A



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIG. 1B





APPROVED	O.G. FIG.
BY	CLASS
DRAFTSMAN	SUBCLASS

Taxol (0.625 nM) + CV787 (MOI=0.01)




FIG. 2



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		




FIG. 3



APPROVED BY DRAFTSMAN	O.G. FIG.	
	CLASS	SUBCLASS

CV787 (moi=0.01) + Taxotere (3.12nM)




FIG. 4

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		



Mitoxantrone (100 nM) + CV787 (moi=0.1)




FIG. 5

Etoposide (500 ng/ml) + CV787 (moi=0.01)





FIG. 6

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		





APPROVED	O.G. FIG.
BY	CLASS
DRAFTSMAN	SUBCLASS

CV787 (moi=0.01) + Doxorubicin (50 ng/ml)





FIG. 7



APPROVED	O.G. FIG.
BY	CLASS
DRAFTSMAN	SUBCLASS


Cisplatin (8.25 μ M) + CV787 (moi=0.1)



Treatment

FIG. 8

5-Fluorouracil (35 μ M) + CV787 (moi=0.01)



Treatment

FIG. 9

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		



CV787 (moi=0.01) + ^{137}Cs (2 Gy)




FIG. 10

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		



Virus Yield (LNCaP)




FIG. 11

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		





APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		




FIG. 12



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

Taxol Does not Alter CV787's Specificity




FIG. 13



APPROVED	O.G. FIG.
BY	CLASS
DRAFTSMAN	SUBCLASS

Specificity of CV787 + Mitoxantrone




FIG. 14



CV790 0.01moi/Doxorubicin 10ng/ml




FIG. 15



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

10ng/ml Doxorubicin first,
then 0.01 MOI CV790




FIG. 16

0.01 MOI CV790 and 10ng/ml Doxorubicin together




FIG. 17



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		



APPROVED	O.C. FIG.
BY	CLASS
DRAFTSMAN	SUBCLASS

CV790 0.1moi/Cisplatin 1ug/ml




FIG. 18

CV790 0.1moi/Taxol 0.5ng/ml




FIG. 19



APPROVED	O.C. H.G.
BY	CLASS
DRAFTSMAN	SUBCLASS

CV790 0.1moi/5-FU 10ng/ml




FIG. 20



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

CV790 0.1moi/Mitoxantrone 4ng/ml




FIG. 21

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		





APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

CV790 0.1moi/Mitomycin C 10ng/ml





FIG. 22



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

Tumor Volume of LNCaP Xenograft Treated with CV787 and Taxol



—◆— Control —▲— CV787, 10⁷p/mm³ —●— Taxol, 15 mg/kg —■— CV787/Taxol

FIG. 23



APPROVED	C.S. FIG.
BY	CLASS
DRAFTSMAN	SUBCLASS

Tumor Volume of LNCaP Xenograft




FIG. 24

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

Tumor Volume of LNCaP Xenograft Treated with CV787 and Taxol




FIG. 25



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

Tumor Volume of LNCaP Xenograft Treated with CV787 and Mitoxantrone




FIG. 26



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

Tumor Volume of LNCaP Xenografts Treated with CV787 and Estramustine





FIG. 27



LNCaP Xenograft Treated with CV787 and Docetaxel



Weeks After Treatment

FIG. 28



LNCaP Xenograft Treated with CV787 and Docetaxel

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		





FIG. 29



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

Tumor Volume of Hep3B Treated with CV790 and Doxorubicin



Weeks After Treatment

—◆— Control —●— CV790(1x10¹¹) —▲— Doxorubicin(10mg/Kg) —■— CV790/Doxo

FIG. 30

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		



Tumor Volume of Hep3B Xenograft Treated with CV890 and Doxorubicin




FIG. 31



APPROVED	O.G. FIG.
BY	CLASS
DRAFTSMAN	SUBCLASS

Cell Viability

Radiation (6Gy) + CV787(moi=0.1)




FIG. 32



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		




FIG. 33



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		





FIG. 34



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

Virus Yield

Radiation (6Gy) + CV787(moi=0.1)



—●— CV787 —■— Radiation+CV787

FIG. 35



APPROVED	O.G. FIG.
BY	CLASS
DRAFTSMAN	SUBCLASS




FIG. 36



FIG. 37

G ATG ACC GGC TCA ACC ATC GCG CCC ACA ACG GAC TAT CGC AAC ACC
46

Met Thr Gly Ser Thr Ile Ala Pro Thr Thr Asp Tyr Arg Asn Thr
1 5 10 15

ACT GCT ACC GGA CTA ACA TCT GCC CTA AAT TTA CCC CAA GTT CAT GCC
94

Thr Ala Thr Gly Leu Thr Ser Ala Leu Asn Leu Pro Gln Val His Ala
20 25 30

TTT GTC AAT GAC TGG GCG AGC TTG GAC ATG TGG TGG TTT TCC ATA GCG
142

Phe Val Asn Asp Trp Ala Ser Leu Asp Met Trp Trp Phe Ser Ile Ala
35 40 45

CTT ATG TTT GTT TGC CTT ATT ATT ATG TGG CTT ATT TGT TGC CTA AAG
190

Leu Met Phe Val Cys Leu Ile Ile Met Trp Leu Ile Cys Cys Leu Lys
50 55 60

CGC AGA CGC GCC AGA CCC CCC ATC TAT AGG CCT ATC ATT GTG CTC AAC
238

Arg Arg Arg Ala Arg Pro Pro Ile Tyr Arg Pro Ile Ile Val Leu Asn
65 70 75

CCA CAC AAT GAA AAA ATT CAT AGA TTG GAC GGT CTG AAA CCA TGT TCT
286

Pro His Asn Glu Lys Ile His Arg Leu Asp Gly Leu Lys Pro Cys Ser
80 85 90 95

CTT CTT TTA CAG TAT GAT TAA (SEQ ID NO: 17)
307

Leu Leu Leu Gln Tyr Asp (SEQ ID NO: 18)
100

APPROVED BY DRAFTSMAN	O.G. FIG.	SUBCLASS
	CLASS	

CIPRI
 JAN 30 2003
 PATENT & TRADEMARK

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		




FIG. 38

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		




FIG. 39

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

CIP
 JAN 30 2003
 PATENT & TRADEMARK OFFICE

Virus Yield of CV884

- CV802
- CV882
- CV884





FIG. 40



APPROVED	O.G. FIG.
BY	CLASS
DRAFTSMAN	SUBCLASS

Structure of CV876, CV882 and CV884




FIG. 41